According to CNBC, SpaceX fell 11% after releasing its first quarterly report since going public in June. The Elon Musk-led company reported second-quarter capital expenditures of $18.37 billion, largely driven by artificial intelligence and up 550% from a year earlier. Revenue reached $7.81 billio…
Q2 2026 saw 48% revenue growth and 33% higher non-GAAP EPS, driven by strong incretin and key product sales. Updated 2026 guidance reflects robust demand, expanded access, and pipeline progress, with significant investments in R&D and acquisitions.Original document: Eli Lilly and Company [LLY] Slid…
Eli Lilly NYSE:LLY will give a limited number of patients access to retatrutide, its experimental obesity drug, before U.S. approval, the company said. A spokesperson said it is "medically appropriate to make authentic retatrutide available before FDA approval," consistent with agency guidance, and…
Eli Lilly (LLY) said on Monday that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation to its experimental cancer drug for advanced pancreatic cancer, extending the drug’s fast-track regulatory status beyond lung cancer.LLY shares are down marginally in early tradi…
After a week dominated by mega-cap earnings, with Microsoft Corp. (NASDAQ:MSFT) and Amazon.com Inc. (NASDAQ:AMZN) sharply exceeding expectations while Apple Inc. (NASDAQ:AAPL) and Meta Platforms Inc. (NASDAQ:META) were punished over margin concerns, the first week of August brings a different cast…
Eli Lilly (LLY) leads the GLP-1 injectable market with tirzepatide (Mounjaro, Zepbound) and is developing retatrutide, which showed large weight-loss in trials and may launch in th
Eli Lilly NYSE:LLY and contract manufacturer Resilience will invest $750 million to expand pharmaceutical production in the Cincinnati region, adding Lilly's KwikPen injectable device to Resilience's operations. Lilly shares are down 2.24% intraday.The expansion creates at least 400 high-skilled jo…
Scribe Therapeutics NASDAQ:SCTX, a clinical-stage developer of gene therapies for heart disease, surged 67% on Friday after raising $128.7 million in an upsized initial public offering. The Alameda, California-based biotechnology company opened at $25 per share in New York, significantly above its…
Novo Nordisk (NVO) is escalating its legal battle with Eli Lilly (LLY), seeking a preliminary U.S. court injunction to immediately block Lilly’s advertisements for blockbuster diabetes and weight-loss drugs, Zepbound and Mounjaro.According to a report by Reuters on Friday, Novo argued that Lilly’s…
Eli Lilly (LLY) was in the limelight in pre-market trading on Thursday, after the pharmaceutical giant reported positive topline results from two late-stage clinical trials of its investigational obesity drug Retatrutide, strengthening its position in the rapidly growing weight-loss market as compe…
Eli Lilly's Surmount-5: Zepbound patients lost ~20.2% body weight (~50 lb) vs Wegovy's 13.7% (~33 lb); newer higher-dose Wegovy study shows ~47 lb loss.Novo Nordisk sued Eli Lilly
Novo Nordisk (NOVO_B) filed a lawsuit accusing Eli Lilly NYSE:LLY of running a "deliberately false" advertising campaign about the comparative effectiveness of their competing obesity and diabetes drugs. Novo Nordisk alleges Lilly cited outdated clinical trial data to claim its obesity drug Zepboun…
Novo Nordisk (NVO) filed a lawsuit against Eli Lilly (LLY) on Monday, accusing its rival of running misleading nationwide advertising campaigns for its blockbuster diabetes and weight-loss drugs, Zepbound and Mounjaro.At the time of writing, NVO stock was down more than 1% while LLY shares edged 0…
Bristol Myers Squibb NYSE:BMY, a drugmaker focused on creating new medicines, is expanding its three-year partnership with Nvidia, a chipmaker providing artificial intelligence computing technology, to increase the power of its AI factory. Bristol Myers said the system is being used to develop medi…
Shares of AtaiBeckley (ATAI) edged lower in pre-market trade on Monday after H.C Wainwright and Berenberg delivered another set of downgrades from Wall Street following the company’s acquisition by Eli Lilly (LLY) last week.ATAI’s stock fell nearly 1% in pre-market trading but continued to trade at…
Eli Lilly (NYSE:LLY) reported blockbuster Q1 results driven by Mounjaro/Zepbound and raised FY guidance, while expanding deals—buying AtaiBeckley and winning PBM support for Foundayo—amid mixed forecasts, revived patent litigation and takeover chatter around oncology assets.Previous Week Recap…
ARK Investment Management founder-CEO Cathie Wood cheered Eli Lilly’s $3.8 billion AtaiBeckley acquisition on Sunday, calling it a “well-deserved” payoff for shareholders and a validation of Christian Angermayer’s psychedelic vision.ATAI stock rose 1% on Friday, adding 40% over the past five sessio…
Eli Lilly NYSE:LLY agreed to buy psychedelic drugmaker AtaiBeckley for up to $3.8 billion, sending the target's shares sharply higher in premarket trading.Lilly will pay $6.75 per share in cash, valuing AtaiBeckley at about $2.8 billion upfront. Investors could receive another $2.50 per share, or r…
Eli Lilly (LLY, Financials), a global pharmaceutical company best known for diabetes, obesity and neuroscience treatments, has agreed to buy AtaiBeckley for as much as $3.8 billion.The deal brings Lilly into the growing market for psychedelic-based medicines. Its main prize is BPL-003, a nasal spra…
taiBeckley NASDAQ:ATAI, a New York-based developer of psychedelic-based treatments for mental health conditions, rose 34.70% premarket after Eli Lilly NYSE:LLY said it would acquire the company for up to $3.8 billion. Lilly will pay $6.75 a share in cash, or about $2.8 billion, a 26% premium to Wed…
